Pages that link to "Q24673373"

The following pages link to Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer( ) CD8( ) T cells in humans (Q24673373):

Displaying 43 items.

• Adoptive immunotherapy for cancer: building on success (Q24546258) (← links)
• Immune activation and CD8 T-cell differentiation towards senescence in HIV-1 infection (Q24795912) (← links)
• Authors' Reply (Q24805683) (← links)
• Structures of MART-126/27–35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell Recognition (Q27647534) (← links)
• T-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen Targeting (Q27672418) (← links)
• Decreased specific CD8 T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide (Q33246123) (← links)
• Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen (Q33322422) (← links)
• Profile of a Serial Killer: Cellular and Molecular Approaches to Study Individual Cytotoxic T‐Cells following Therapeutic Vaccination (Q34338725) (← links)
• In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells (Q34560957) (← links)
• The human T cell response to melanoma antigens (Q34587175) (← links)
• Primed tumor-reactive multifunctional CD62L human CD8 T cells for immunotherapy (Q34863769) (← links)
• CD8 T-cell memory in tumor immunology and immunotherapy (Q34768139) (← links)
• Human papillomavirus type 16 E7 peptide-directed CD8 T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein (Q34975376) (← links)
• T-cell responses of vaccinated cancer patients (Q35084253) (← links)
• Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides (Q35160569) (← links)
• Enhancement of T cell recruitment and infiltration into tumours. (Q35178939) (← links)
• Specific roles of each TCR hemichain in generating functional chain-centric TCR. (Q35205495) (← links)
• Broadening the repertoire of melanoma-associated T-cell epitopes. (Q35546276) (← links)
• Cumulative autoimmunity: T cell clones recognizing several self-epitopes exhibit enhanced pathogenicity (Q35928352) (← links)
• Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? (Q36150417) (← links)
• Reduced naïve CD8( ) T-cell priming efficacy in elderly adults (Q36475259) (← links)
• CD4( ) and CD8( ) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells (Q36748257) (← links)
• Tumour immunity: effector response to tumour and role of the microenvironment (Q37085136) (← links)
• Self-antigen-specific CD8 T cell precursor frequency determines the quality of the antitumor immune response. (Q37273315) (← links)
• Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen (Q37570169) (← links)
• Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy (Q38266427) (← links)
• TCR-ligand dissociation rate is a robust and stable biomarker of CD8 T cell potency (Q38671405) (← links)
• Role of the MHC restriction during maturation of antigen-specific human T cells in the thymus. (Q38814475) (← links)
• Priming of Qualitatively Superior Human Effector CD8 T Cells Using TLR8 Ligand Combined with FLT3 Ligand (Q38816516) (← links)
• Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells (Q38993201) (← links)
• Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer. (Q39516809) (← links)
• Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8 T cells (Q42003336) (← links)
• Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities (Q42145973) (← links)
• Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients (Q43147458) (← links)
• Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. (Q44783246) (← links)
• Multiparameter precursor analysis of T-cell responses to antigen (Q45274339) (← links)
• CD28(neg.) T lymphocytes of a melanoma patient harbor tumor immunity and a high frequency of germline-encoded and public TCRs (Q47579913) (← links)
• High frequencies of functionally impaired cytokeratin 18-specific CD8 T cells in healthy HLA-A2 donors. (Q53659154) (← links)
• Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification (Q63976951) (← links)
• T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability. (Q64973005) (← links)
• New MAGE‐4 antigenic peptide recognized by cytolytic T lymphocytes on HLA‐A1 tumor cells (Q79293656) (← links)
• Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans (Q87654030) (← links)
• The Origin and Immune Recognition of Tumor-Specific Antigens (Q99548643) (← links)